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Abstract  
BACKGROUND: Autism and Fragile X syndrome are intertwined. This study aimed at assessing 
Serotonin, Glutamate, and Gama Amino Butyric Acid (GABA) in autism and Fragile X syndrome 
patients and to detect possible neurochemical similarities between the 2 disorders that can be used 
as metabolic biomarkers. 
DESIGN AND METHODS: Eighty subjects divided into four groups, two diseased groups (20 male 
patients with Autism and 20 males with Fragile X syndrome) and two control groups (20 
neurotypical male controls and 20 Down syndrome male patients) were included. Estimation of 
Serotonin, Glutamate and GABA were done using Enzyme linked Immunosorbent Assay (ELISA), 
Tandem Mass Spectrometry and high-pressure liquid chromatography (HPLC), respectively. 
RESULTS: Serotonin was, exclusively, significantly low in autistic children. GABA was significantly 
high in both autistic and Fragile X children only, but not in Down syndrome children. Glutamate was 
significantly high in children with autism, Fragile X and Down syndrome Children. 
CONCLUSIONS: Autism and Fragile X syndrome share some neurochemical similarities with 
regards of high Glutamate and GABA levels while Serotonin was significantly different in the 2 
disorders and may be used a unique biomarker for autism. 
 
 
 
 
 
 
 
Introduction 
Autism is a complex disorder affecting 
neurologic development. It is characterized by deficits 
in social interaction, disrupted verbal and nonverbal 
communication, and restricted repetitive behavior and 
interests [1]. It usually manifests before 3 years of 
age. Previously, autism was thought to be a rare 
disorder; however the number of reported cases rose 
significantly during the 1990s. According to the latest 
estimates from CDC’s Autism and Developmental 
Disabilities Monitoring (ADDM) Network, about 1 in 68 
children has been identified with autism spectrum 
disorder (ASD) (CDC, 2014) [2].  Autism heritability is 
estimated to be as 90% under a multifactorial 
threshold model (Hallmayer et al., 2011) [3].  
Mendelian form of autism was identified with co 
morbid Intellectual Disability (ID) and epilepsy, 
associated with low plasma levels of branched chain 
amino acids (BCAAs).The mechanism by which 
abnormal amino acid levels may lead to autism, 
Intellectual Disability (ID), and epilepsy needs to be 
elucidated. Dietary supplementation with BCAAs 
reversed some of the neurological phenotypes in mice 
[4].  
Fragile X syndrome (FXS) is considered to be 
the most common single gene cause of autism 
(McLennan et al., 2011) [5]. It is estimated to affect 
1:2500 to 1:4000 individuals (See Recent reference). 
Recent study in 2014 has reported that the frequency 
of the full mutation was 1.4 (95% CI: 0.1–3.1) per 
10,000 males and 0.9 (95% CI: 0.0–2.9) per 10,000 
females (1:7,143 and 1:11,111, respectively) in the 
total population. The premutation frequency was 11.7 
(95% CI: 6.0–18.7) per 10,000 males and 34.4 (95% 
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CI: 6.3–83.3) per 10,000 for females (1:855 and 
1:291, respectively) in the total population. The 
prevalence of female carriers of the premutation in the 
normal population was 34.4 (95% CI: 8.9–60.3) per 
10,000, or 1:291 (Hunter et al., 2014) [6]. 
Fragile X and autism are closely related. Two 
to seven percent of children have a mutation in Fragile 
X Mental Retardation 1 (FMR1) gene [7]. In the mean 
time, about 15-30% of Fragile X children have autistic 
features [8]. Fragile X mental retardation 
protein(FMRP) regulates the  translation of 
neuroligins, neurorexins, SHANK, PTEN, CYFIP, and 
PSD95 proteins, which are associated with autism 
[7].FMR1 gene regulates the expression of other 
genes and affect synaptic formation and plasticity [9]. 
It is a neuronal and gonadal protein with key roles in 
neuroplasticity and neuronal translation (Soden et al., 
2010) [10]. Therefore, decline or absence of FMRP, 
may be associated with significant alterations 
indifferent proteins that affect brain development, 
ending in developmental disorders, particularly autism 
(Darnell, 2011) [11]. 
Several studies have determined different 
neurotransmitters in children with autism; however, 
only one study in 1984 has estimated serotonin level 
in Fragile X syndrome patients with and without 
autism. Here, we evaluate 3 neurotransmitters in the 2 
intertwined disorders, autism and Fragile X Syndrome. 
To our knowledge, this is the first study that estimates 
Glutamate and GABA levels in Fragile X compared to 
autistic, Down Syndrome (DS) and neurotypical 
children. 
This study aimed at detection of 
neurobiological similarities between Autism and FXS 
so targeted treatment currently being studied in FXS 
can be applied to autistic patients. Also assessment of 
these neurotransmitters could be used as metabolic 
biomarkers for Autism or FXS. 
 
Subjects and Methods 
The present study included 80 subjects 
divided into 4 groups, 2 diseased groups (20 male 
patients with Autism and 20 males with FXS) and 2 
control groups (20 neurotypical male controls and 20 
Down syndrome male patients). All the children 
enrolled in the present study aged from 3-11 years 
old. Autism, FXS and DS patients were selected from 
The Autism Disorders Clinic, Medical Research 
Center of Excellence, National Research Center 
(NRC), Cairo, Egypt. The ethical approval of the NRC 
ethical committee was obtained prior to the study and 
a written informed consent was provided by the 
parents of autistic children. 
All patients were subjected to careful pedigree 
construction and complete diagnostic workup 
including medical, psychiatric, psychological and 
neurological evaluation. Autistic children were 
clinically diagnosed with Autism Diagnostic Interview 
Revised (ADI-R) [12] and degree of severity was 
assessed by Childhood autism rating scale (CARS) 
[13]. Nine autistic patients out of 20 were classified as 
having severe autism, while the other 11 were having 
mild to moderate autism. Fragile X syndrome patients 
were diagnosed clinically by Hagerman checklist [14] 
and in the laboratory by DNA Fragile X test. Fragile X 
patients were classified according to the presence of 
autistic features into 6 with autistic features and 14 
without autistic features. Down syndrome patients 
were subjected to karyotyping. Exclusion criteria 
included neurological, metabolic, endocrine, 
cardiovascular, pulmonary, liver, kidney or other 
medical disease. 
Metabolic biomarkers as Serotonin, GABA 
and Glutamate were estimated in the 4 groups. The 
aim of including DS as a control group was to see if 
these metabolic biomarkers are specific to certain 
disease as Fragile X disease and autism or it is 
present in other disorders associated with mental 
retardation as DS.Threeml of venous blood samples 
were taken from the children on EDTA (Ethylene 
Diamine Tetra Acetate) vacuum tubes. Serotonin 
assay was done using Serotonin ELISA kit (DIA 
source Immunoassay S.A. Rue de Industrie 8, 1400 
Nivelles, Belgium).Calibration curve was obtained by 
plotting the absorbance readings against the 
corresponding standard concentrations. Plasma 
GABA levels were measured by high-performance 
liquid chromatography-electrochemical method [15]. 
Calibration curve was drawn using four standard 
solutions of GABA. Glutamate was assayed from 
dried blood spots using Mass Spectrometry/ Mass 
Spectrometry (MS/MS) The detector monitors the ion 
current, amplifies it and the signal is then transmitted 
to the data system where it is recorded in the form of 
mass spectra [16]. 
Analysis of results was performed using 
statistical package for social science(SPSS) 
software(SPSS Inc., Chicago, IL, USA) ,version 15 for 
Microsoft Windows. Multivariate analysis was used to 
compare between the different groups [17].  
 
Results 
Autistic children had a significantly very low 
serotonin level when compared to the 3 other groups 
(Fragile X Syndrome, DS and neurotypical children) 
(Table 1). On the contrary, FXS syndrome showed 
significantly high levels when compared to patients 
with autism, DS and normal healthy children. Down 
syndrome cases showed lower serotonin levels 
compared to neurotypical children but this difference 
was not statistically significant. 
The second neurotransmitter assayed was 
Glutamate     (Table  2).     Autism     cases     showed  
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Table 1: Serotonin levels in the different studied groups 
(ng/ml). 
Group 
Mean ± SD 
Group 
Mean ± SD 
P value 
Autism Normal 
P<0.0001** 
79.95 ±  45.48 207.50  ±  128.37 
FXS Normal 
P<0.0001** 
1182.93  ± 1060.27 207.50  ±  128.37 
Autism DS 
P<0.0001** 
79.95 ±  45.48 186.75 ±  129.88 
FXS DS 
P<0.0001** 
1182.93  ± 1060.27 186.75 ±  129.88 
Normal DS 
P>0.05 
207.50  ±  128.37 186.75 ±  129.88 
Autism FXS 
P<0.0001** 
79.95 ±  45.48 1182.93  ± 1060.27 
**Significant difference. 
 
significantly high levels of Glutamate compared to 
other groups (FXS, DS, and normal controls). 
Meanwhile, cases with FXS demonstrated significantly 
higher glutamate levels compared to DS patients and 
normal healthy controls. On the other hand, when the 
2 control groups were compared to each other, DS 
children had significantly higher Glutamate levels 
compared to neurotypical children. 
Table 2: Glutamate levels in the different studied groups 
(µmol/L). 
Group 
Mean ± SD 
Group 
Mean ± SD 
P Value 
Autism Normal 
P<0.0001** 
164.09 ± 33.29 67.05 ±  15.05 
FXS Normal 
P<0.0001** 
121.18 ±   24.19 67.05 ±  15.05 
Autism DS 
P<0.0001** 
164.09 ± 33.29 85.67 ±   9.40 
FXS DS 
P<0.0001** 
121.18 ±   24.19 85.67 ±   9.40 
Normal DS 
P<0.0001** 
67.05 ±  15.05 85.67 ±   9.40 
Autism FXS 
P<0.0001** 
164.09 ± 33.29 121.18 ±   24.19 
 **Significant difference. 
 
GABA level in autism was significantly higher 
(117.90 ± 33.13) when compared to the neurotypical 
children (78.75 ± 21.63) and DS (66.40 ± 27.47) 
(Table 3). Also, GABA in FXS children was also 
significantly higher (125.35 ± 49.19) when compared 
to neurotypical children and DS children. Interestingly, 
FXS children had higher GABA levels than children 
with autism; however, this difference was not 
statistically significant. When the 2 control groups 
were compared to each other, DS children showed 
lower GABA levels (66.40 ± 27.47) than control group 
(78.75 ± 21.63). However, this difference was not 
statistically significant. 
Table 3: GABA levels in the different studied groups (ng/ml). 
Group 
Mean± SD 
Group 
Mean± SD 
P Value 
Autism Normal 
P<0.0001** 
117.90 ± 33.13 78.75 ±  21.63 
FXS Normal 
P<0.0001** 
125.35  ±  49.19 78.75 ±  21.63 
Autism DS 
P<0.0001** 
117.90 ± 33.13 66.40 ± 27.47 
FXS DS 
P<0.0001** 
125.35  ±  49.19 66.40 ± 27.47 
Normal DS 
P>0.05 
78.75 ±  21.63 66.40 ± 27.47 
Autism FXS 
P>0.05 
117.90 ± 33.13 125.35  ±  49.19 
**Significant difference. 
 
The twenty autistic children were also 
classified according to  the   Childhood  Autism Rating  
Table 4: Neurotransmitters in mild-moderate and severe 
autism. 
Neurotransmitters 
Mild-Moderate 
Autism 
Severe Autism P Value 
Serotonin (ng/ml) 73.11  ±  40.87 85.54±   50.18 P>0.05 
Glutamate (µmol/L) 1.48 ±  43.94 1.76 ±  13.21 P>0.05 
GABA (ng/ml) 1.35  ±  24.94 1.03 ±  32.84 P>0.05 
 
Scale into 9 with severe autism and 11 with mild to 
moderate autism. Children with severe autism showed 
higher but non-significant levels of glutamate and 
serotonin when compared to mild-moderate autism 
(Table 4). Meanwhile, GABA levels showed non-
significantly lower levels in severe autism compared to 
mild-moderate autism. Also Fragile X children with 
autistic features had non-significantly higher levels of 
Glutamate and Serotonin compared to Fragile X 
children without autistic features (Table 5). 
Table 5: Neurotransmitters in FXS with and without autistic 
features. 
Neurotransmitters 
FXS with autistic 
features 
FXS without 
autistic features 
P Value 
Serotonin (ng/ml) 1563.66 ±  1168 1019 ±  1010.96 P>0.05 
Glutamate (µmol/L) 125.46  ±   19.76 119 ±    26.33 P>0.05 
GABA (ng/ml) 112.50 ±    60.7 130  ±  44.8 P>0.05 
 
 
Discussion 
The present study evaluated 3 
neurotransmitters in autism compared to Fragile X 
Syndrome to assess the possibility of neurochemical 
similarities between the 2 disorders. Autism and 
Fragile X syndrome have an overlap at the molecular 
level [18]. Proteins that regulate the balance of activity 
in brain glutamate and GABA systems, including 
PSD95 and Arc were found to be defective. These 
proteins are directly regulated by FMRP [18]. 
Previous studies have estimated different 
neurotransmitters in autism compared either to their 
relatives or normal healthy children. To our 
knowledge, this is the first study that evaluated 
Serotonin, Glutamate and GABA in autism compared 
to Fragile X syndrome; also it is first study to evaluate 
Glutamate and GABA in Fragile X Syndrome. 
The most studied neurotransmitter in autism 
is Serotonin which is related to many human 
behaviors including mood, sleep, appetite and 
memory. An early study in 1961 showed an increased 
levels of endogenous 5-HT in whole blood in 26% of 
autistic children [19]. These results have also been 
confirmed by other studies [20]. 
In the present study, significantly low levels of 
plasma serotonin were detected in autism when 
compared to the other 2 groups (Fragile X Syndrome, 
and neurotypical children).These results are in 
agreement with those of Spivak et al., [21] who 
estimated plasma serotonin in 10 autistic children 
compared to 12 neurotypical children and concluded 
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that low plasma serotonin levels may have a role in 
the pathophysiology and symptomatology of autism, 
However another study in Saudi Arabia [22] detected 
high plasma serotonin levels in 16 Saudi autistic 
children compared to 16 neurotypical controls and 
concluded that high lead level is associated with 
remarkable high levels of serotonin. 
The detection of low plasma serotonin levels 
in our study can be explained by the possibility of 
enhanced serotonin accumulation in platelet [23] that 
subsequently associated with increased platelet 
serotonin levels and parallel-diminished free plasma 
serotonin levels. Also low cerebrospinal fluid levels of 
5- hydroxyindoleaceticacid [24] and low serotonin 
urinary excretion rate in autism [25] supports our 
findings. 
High significant levels of serotonin in Fragile X 
were detected in present study compared to autism, 
neurotypical children and D.S. Another study reported 
normal serotonin levels in 12 fragile autistic children 
out of 13 and only one had low serotonin levels [26]. 
High serum glutamate levels were reported in 
autism compared to normal controls [27, 28].  Plasma 
amino acid analyses were carried out on a recent 
cohort of 138 autistic children and 138 normal controls 
using reverse-phase HPLC, it concluded that elevated 
levels of excitatory amino acids (glutamate and 
asparagine), decreased essential amino acids 
(phenylalanine, tryptophan and methionine) and 
decreased precursors of neurotransmitters (tyrosine 
and tryptophan) are the distinct characteristics of 
plasma amino acid profile of autistic children  
(Naushad et al., 2013) [29]. 
Another study also reported high levels of 
glutamate and homocystein in autism while the levels 
of glutamine and tryptophan are decreased 
(Ghanizadeh 2013) [30]. 
Our study replicated these results and could 
explain some clinical symptoms accompanied with 
autism as seizures and Electroencephalogram (EEG) 
abnormalities. Valproic acid is a mood stabilizer and 
was found to be effective intreanting autistic patients 
with or without clinical seizures but with epileptiform 
abnormalities [31].This explains the high rates of 
seizure disorders in autism that are due to high 
glutamate levels. 
Increased glutamate levels in autism could be 
explained by presence of low levels of Pyridoxal 
Phosphate (PLP) in children with autism due to very 
low activity of pyridoxal kinase leading to blockage of 
glutamate utilization [32]. Also, alterations in the 
glutamate transporter or in glutaminase or glutamine 
synthetase activity would potentially affect glutamate 
levels [33]. 
Few studies had been conducted to assess 
the Glutamate in Fragile X syndrome, one of these 
studies was by Gruss and Braun [34] who reported 
unaltered Glutamate in all regions of brain in both 
ages (Juvenile and Adult). The present study reported 
high significant levels of Glutamate in autism 
compared to neurotypical children and to D.S. 
The final neurotransmitter that was assessed 
in this study was GABA which is known to play a 
crucial role in synaptic tuning and neuronal wiring in 
late pre and early postnatal days (Ben Ari et al.,, 
2012) [35]. Studies from animal models of ASDs 
indicate that a dysfunction in GABAergic signaling 
within particular neuronal circuits may account for 
most of the clinical symptoms found in autistic 
patients. The high co-morbidity of ASDs with epilepsy 
(30% of cases) further confirms this issue (Frye et al., 
2013) [36]. 
Plasma GABA was significantly high in 
autistic children compared to neurotypical  and Down 
syndrome. Our results were in concordant with 
Dhossche et al. [37]. However, they detected 
significantly higher plasma GABA levels in 9 
youngsters with autism than in 9 youngsters with 
Attention Deficit Hyperactivity Disorder (ADHD). 
Several studies also supported the high GABA levels 
in autism. A study had been conducted in Saudi 
Arabia showed high levels of lead and GABA in 
plasma [22]. Increased plasma GABA levels were 
found to be associated with reduced numbers of 
neurons expressing GABA and low brain GABA levels 
[38]. Divalproex is effective in treating autistic children 
who showed improved behavior due to elevation of 
brain GABA by inhibiting catabolic enzyme of GABA 
(GABA Transaminase) [39].  
Some clinical observations have been added 
to support the role of GABA in autism [37]. There is 
increasing evidence that GABA neuronal dysfunction 
is implicated in various psychiatric disorders including 
schizophrenia, mood disorders, and anxiety disorders 
[40]. In some disorders, GABA dysfunction may occur 
in conjunction with abnormalities in reelin, a 
glycoprotein involved in the developmental regulation 
of GABAergic transmission Reductions of reelin in the 
cerebellar cortex of people with autism have also 
been reported [41]. Abnormalities on the long arm of 
chromosome15 have been found in a small proportion 
of autistic people. A cluster of genes coding for GABA 
A receptor subunits have been identified in that 
location (chromosome15q11-13). The GABA receptor 
beta-3 subunit gene has been implicated as an autism 
susceptibility locus in previous genetic studies, 
although the evidence is far from conclusive [42]. It is 
possible that in a subgroup of autistic people, GABA 
dysfunction is present in some brain areas owing to 
abnormalities of the assembly of GABA A receptor 
subunits into the GABA receptor complex. Thirdly, a 
few reports have suggested that benzodiazepines, 
i.e., positive modulators of GABA metabolism, have a 
negative and even paradoxical effect in autistic 
people.  
Meguid et al. Autism and Fragile X: Is There a Neurochemical Link? 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
OA Maced J Med Sci. 2014 Dec 15; 2(4):551-556.                                                                                                                                                                         555 
 
Finally, the present study detected high 
significant levels of GABA in Fragile X children 
compared to normal healthy children and to D.S. 
Previous study [34] reported that GABA was 
significantly higher in the brainstem of FMR 1 
knockout mice than in wild type.  
The involvement of GABAA receptors in 
ASDs was provided by genetic studies that have 
revealed submicroscopic abnormalities known as 
“copy-number variations” in chromosomal loci 15q11–
q13, which contains a number of genes encoding for 
GABAA receptor subunits Coghlan et al., 2012  [43]. 
It became more evident that autism and 
Fragile X Syndrome share a lot on the molecular and 
biochemical levels, so treatments that are used for 
FXS can also be beneficial for some autistic patients. 
There are large list of genes implicated in autism 
which can be mapped onto specific brain pathways 
[18]. Fragile X syndrome and autism are intertwined. 
Up regulation of m Glu R 5 pathways wand down 
regulation of GABA A pathways were reported in 
Fragile X children and nowadays treatment are aiming 
at reversing these problems [44]. These treatment can 
also be very useful for some children who are having 
autism. 
In conclusion, the present study showed that 
low serotonin levels was exclusively and unique to 
autistic patients and it can be consider as a metabolic 
marker for autism. Also we found that autism and FXS 
share neurobiological similarities as GABA was 
significantly high in both disorders than neurotypical 
children, meanwhile it was specific to Autism and FXS 
as GABA level was not high in D.S. On the contrary 
DS showed lower (non significant) GABA levels than 
neurotypical children. With regards Glutamate, it was 
high in the 3 disorders but with the highest levels in 
Autism followed by FXS and DS, respectively. 
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